{"id":8319,"date":"2025-12-19T01:00:00","date_gmt":"2025-12-19T01:00:00","guid":{"rendered":"https:\/\/bostonsp.com\/?p=8319"},"modified":"2026-07-27T14:34:24","modified_gmt":"2026-07-27T14:34:24","slug":"real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients","status":"publish","type":"post","link":"https:\/\/bostonsp.com\/index.php\/2025\/12\/19\/real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients\/","title":{"rendered":"Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients"},"content":{"rendered":"

Dingli, D., De Nigris, E., Leng, S., Farooqui, M. Z. H., Yapici, H. O., Weimer, I., Jiao, W., Hyatt, H., Zhang, X., Lodaya, K., & Obeng-Kusi, M. (2026). Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. Future oncology (London, England), 22(1), 71\u201382. https:\/\/doi.org\/10.1080\/14796694.2025.2600913<\/a><\/span><\/p>\n

View article<\/strong><\/a><\/p>\n\n\n

<\/div>\n\n\n

Abstract<\/h4>\n
\n

Aim
To evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) treated with covalent Bruton\u2019s Tyrosine Kinase inhibitors (cBTKis).<\/p>\n

Methods
Patients initiating cBTKi treatment from 1 January 2020 to 1 January 2023 were identified using claims data. Demographics, first-line (1L) and second-line or later (2L+) therapy, incident CVAEs, and clinical outcomes were assessed.<\/p>\n

Results
In total, 2,163 patients (81.4% in 1L and 18.6% in 2L+) were identified with a mean age of 73.8 \u00b1 9.2\u2009years and 40.6% female. The most common incident CVAEs were hypertension (23.4%), atrial fibrillation (10.2%), ventricular arrhythmias (10.1%), heart failure (8.5%), and atrial flutter (4.2%). Those with CVAEs experienced higher switching to next treatment\u2009+\u2009death and worse overall survival than those without CVAEs. Incidence rates were ~2\u20133 fold lower with acalabrutinib than ibrutinib for hypertension, atrial fibrillation, and atrial flutter. Kaplan-Meier estimates for the likelihood of not experiencing a CVAE were 83% (acalabrutinib) and 72% (ibrutinib) at 12-months.<\/p>\n

Conclusions
Despite improvements in 2nd-generation cBTKi cardiotoxicity, patients with CLL\/SLL receiving cBTKis have a considerable cardiovascular disease burden. These findings highlight the unmet need for CLL\/SLL treatment options with improved efficacy and safety profiles.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Dingli, D., De Nigris, E., Leng, S., Farooqui, M. Z. H., Yapici, H. O., Weimer, I., Jiao, W., Hyatt, H., Zhang, X., Lodaya, K., & Obeng-Kusi, M. (2026). Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. Future oncology (London, England), 22(1), 71\u201382. https:\/\/doi.org\/10.1080\/14796694.2025.2600913<\/a> View article Abstract AimTo evaluate the real-world incidence of […]<\/p>\n","protected":false},"author":9,"featured_media":8321,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"_wpcom_ai_launchpad_first_post":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[9],"tags":[475,478,479,480,481,473,476,99,477],"class_list":["post-8319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications","tag-acalabrutinib","tag-btk-inhibitor","tag-cardiac-complications","tag-cardiac-events","tag-cardiotoxicity","tag-chronic-lymphocytic-leukemia","tag-ibrutinib","tag-real-world-evidence","tag-zanubrutinib"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t